• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影响治疗性蛋白 ADME 性质的关键理化特性。

Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.

机构信息

U.S. Food and Drug Administration, Office of Clinical Pharmacology, DV II, Silver Spring, MD, USA.

出版信息

Adv Exp Med Biol. 2019;1148:115-129. doi: 10.1007/978-981-13-7709-9_6.

DOI:10.1007/978-981-13-7709-9_6
PMID:31482497
Abstract

Therapeutic proteins are a rapidly growing class of drugs in clinical settings. The pharmacokinetics (PK) of therapeutic proteins relies on their absorption, distribution, metabolism, and excretion (ADME) properties. Moreover, the ADME properties of therapeutic proteins are impacted by their physicochemical characteristics. Comprehensive evaluation of these characteristics and their impact on ADME properties are critical to successful drug development. This chapter summarizes all relevant physicochemical characteristics and their effect on ADME properties of therapeutic proteins.

摘要

治疗性蛋白是临床应用中快速发展的一类药物。治疗性蛋白的药代动力学(PK)依赖于其吸收、分布、代谢和排泄(ADME)特性。此外,治疗性蛋白的 ADME 特性受其物理化学特性的影响。全面评估这些特性及其对 ADME 特性的影响,对成功开发药物至关重要。本章总结了治疗性蛋白的所有相关物理化学特性及其对 ADME 特性的影响。

相似文献

1
Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.影响治疗性蛋白 ADME 性质的关键理化特性。
Adv Exp Med Biol. 2019;1148:115-129. doi: 10.1007/978-981-13-7709-9_6.
2
Factors Influencing ADME Properties of Therapeutic Antisense Oligonucleotides: Physicochemical Characteristics and Beyond.影响治疗性反义寡核苷酸ADME特性的因素:物理化学特性及其他
Curr Drug Metab. 2023;24(7):536-552. doi: 10.2174/1389200224666230418092626.
3
Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.治疗自身免疫和炎症疾病的生物疗法的吸收、分布、代谢和排泄(ADME)研究。
AAPS J. 2012 Dec;14(4):714-27. doi: 10.1208/s12248-012-9385-y. Epub 2012 Jul 14.
4
In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development.计算机模拟的吸收、分布、代谢、排泄及药代动力学(ADME-PK):效用与最佳实践。来自国际药品研发质量创新联盟的行业观点。
J Med Chem. 2017 Nov 22;60(22):9097-9113. doi: 10.1021/acs.jmedchem.7b00487. Epub 2017 Jun 27.
5
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.影响治疗性蛋白质ADME特性的关键因素:药物发现与开发中对ADME特性表征的需求。
MAbs. 2016;8(2):229-45. doi: 10.1080/19420862.2015.1115937. Epub 2015 Dec 4.
6
Pharmacokinetics and ADME characterizations of antibody-drug conjugates.抗体药物偶联物的药代动力学和药物代谢动力学特征
Methods Mol Biol. 2013;1045:117-31. doi: 10.1007/978-1-62703-541-5_7.
7
ADME-AP: a database of ADME associated proteins.ADME-AP:一个与药物代谢动力学相关蛋白质的数据库。
Bioinformatics. 2002 Dec;18(12):1699-700. doi: 10.1093/bioinformatics/18.12.1699.
8
Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics.用于描述蛋白质治疗药物的吸收、分布、代谢和排泄的数学模型。
Drug Metab Dispos. 2022 Jun;50(6):867-878. doi: 10.1124/dmd.121.000460. Epub 2022 Feb 23.
9
Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.下一代蛋白质治疗药物的药代动力学和药效学考量
J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):553-71. doi: 10.1007/s10928-015-9447-8. Epub 2015 Sep 15.
10
Absorption, Distribution, Metabolism, and Excretion of Therapeutic Proteins: Current Industry Practices and Future Perspectives.治疗性蛋白的吸收、分布、代谢和排泄:当前行业实践与未来展望。
Drug Metab Dispos. 2022 Jun;50(6):837-845. doi: 10.1124/dmd.121.000461. Epub 2022 Feb 11.

引用本文的文献

1
Development of an mPBPK machine learning framework for early target pharmacology assessment of biotherapeutics.用于生物治疗药物早期靶点药理学评估的mPBPK机器学习框架的开发。
Sci Rep. 2025 Feb 4;15(1):4198. doi: 10.1038/s41598-025-87316-w.
2
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.研究抗体大小、电荷和与 FcRn/抗原结合亲和力对抗体药代动力学的综合影响的最小生理基于药代动力学模型。
J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):477-492. doi: 10.1007/s10928-023-09899-z. Epub 2024 Feb 24.
3

本文引用的文献

1
Optimizing treatment strategies with insulin glargine in Type 2 diabetes.优化甘精胰岛素在2型糖尿病中的治疗策略。
Expert Rev Endocrinol Metab. 2012 Jul;7(4):377-393. doi: 10.1586/eem.12.29.
2
Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.单克隆抗体和 Fc 融合蛋白的药代动力学。
Protein Cell. 2018 Jan;9(1):15-32. doi: 10.1007/s13238-017-0408-4. Epub 2017 Apr 19.
3
Monitoring drug-serum protein interactions for early ADME prediction through Surface Plasmon Resonance technology.通过表面等离子体共振技术监测药物-血清蛋白相互作用以进行早期药物吸收、分布、代谢和排泄预测。
Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises.
推进小分子SARS-CoV-2发现的资源与计算策略:从大流行中吸取的教训及为未来健康危机做准备
Comput Struct Biotechnol J. 2021;19:2537-2548. doi: 10.1016/j.csbj.2021.04.059. Epub 2021 Apr 26.
J Pharm Biomed Anal. 2017 Sep 10;144:188-194. doi: 10.1016/j.jpba.2017.03.054. Epub 2017 Mar 28.
4
Prospective Design of Anti-Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain.用于优化递送至人脑中的抗转铁蛋白受体双特异性抗体的前瞻性设计。
CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):283-91. doi: 10.1002/psp4.12081. Epub 2016 May 17.
5
A comprehensive review of the neonatal Fc receptor and its application in drug delivery.新生儿 Fc 受体及其在药物传递中的应用的全面综述。
Pharmacol Ther. 2016 May;161:22-39. doi: 10.1016/j.pharmthera.2016.03.007. Epub 2016 Mar 22.
6
Single chain antibody fragments with pH dependent binding to FcRn enabled prolonged circulation of therapeutic peptide in vivo.具有 pH 依赖性结合 FcRn 能力的单链抗体片段使治疗性肽在体内的循环时间延长。
J Control Release. 2016 May 10;229:37-47. doi: 10.1016/j.jconrel.2016.03.017. Epub 2016 Mar 15.
7
N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.N-糖基化异质性及其对单克隆抗体和Fc融合蛋白的结构、功能及药代动力学的影响。
Eur J Pharm Biopharm. 2016 Mar;100:94-100. doi: 10.1016/j.ejpb.2016.01.005. Epub 2016 Jan 13.
8
Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.影响治疗性蛋白质ADME特性的关键因素:药物发现与开发中对ADME特性表征的需求。
MAbs. 2016;8(2):229-45. doi: 10.1080/19420862.2015.1115937. Epub 2015 Dec 4.
9
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.癌症免疫疗法中自然杀伤细胞介导的抗体依赖性细胞毒性
Front Immunol. 2015 Jul 27;6:368. doi: 10.3389/fimmu.2015.00368. eCollection 2015.
10
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters.用于延长生物制品半衰期的融合蛋白作为制造生物改良药的一种策略。
BioDrugs. 2015 Aug;29(4):215-39. doi: 10.1007/s40259-015-0133-6.